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Since the discovery of co-receptor dependent αβTCR recognition, considerable effort has
been spent on elucidating the basis of CD4 and CD8 lineage commitment in the thymus.
The latter is responsible for generating mature CD4 helper and CD8αβ cytotoxic T cell
subsets. Although CD4+ and CD8+ T cell recognition of peptide antigens is known to be
MHC class II- and MHC class I-restricted, respectively, the mechanism of single positive
(SP) thymocyte lineage commitment from bipotential double-positive (DP) progenitors is
not fully elucidated. Classical models to explain thymic CD4 vs. CD8 fate determination
have included a stochastic selection model or instructional models. The latter are based
either on strength of signal or duration of signal impacting fate. More recently, differential
co-receptor gene imprinting has been shown to be involved in expression of transcrip-
tion factors impacting cytotoxicT cell development. Here, we address commitment from a
structural perspective, focusing on the nature of co-receptor binding to MHC molecules. By
surveying 58 MHC class II and 224 MHC class I crystal structures in the Protein Data Bank,
it becomes clear that CD4 cannot bind to MHC I molecules, nor can CD8αβ or CD8αα bind
to MHC II molecules. Given that the co-receptor delivers Lck to phosphorylate exposed
CD3 ITAMs within a peptide/MHC (pMHC)-ligated TCR complex to initiate cell signaling,
this strict co-receptor recognition fosters MHC class-restricted SP thymocyte lineage com-
mitment at the DP stage even though both co-receptors are expressed on a single cell.
In short, the binding preference of an αβTCR for a peptide complexed with an MHC mol-
ecule dictates which co-receptor subsequently binds, thereby supporting development of
that subset lineage. How function within the lineage is linked further to biopotential fate
determination is discussed.
Keywords:TCR, co-receptor, lineage commitment, structure, thymocyte development
CO-RECEPTORS: THEIR HISTORY AND FUNCTION
Two major subsets of human T lymphocytes were distinguished
in the 1980s by surface expression of CD8 and CD4 as defined
by monoclonal antibodies. These were shown to represent cyto-
toxic and helper T lymphocytes, respectively (1–4). Analysis of T
cell clones revealed that CD8+ T cells were MHC class I restricted
whereas CD4+ T cells were MHC class II restricted in their TCR
recognition. The involvement of CD4 and CD8 in antigen-specific
T cell recognition, despite their invariant structures, suggested that
CD4 and CD8 might function as co-receptors in cognate recogni-
tion (4). In such a model, the co-receptors interact with conserved
segments of MHC molecules (CD8 with MHCI and CD4 with
MHCII) whereas the αβTCR recognizes a specific peptide bound
to a polymorphic segment of the same MHC molecule. Subsequent
structural studies over the last two decades validated this hypothe-
sis, revealing the bidentate interaction of a TCR and a co-receptor
with the peptide/MHC (pMHC) in a trimolecular complex (5–10).
Given that recent reviews have highlighted detailed structures
of the co-receptors (11, 12), these shall not be reviewed herein.
Instead, features relevant to the biologic function of co-receptors
in the mature peripheral T cell and thymocyte compartments are
highlighted.
The CD8 transmembrane co-receptor is encoded by two dis-
tinct genes: CD8α and CD8β. Each consists of a single Ig-like
domain followed by a lengthy stalk region of 30–50 residues with
multiple O-glycosylated adducts, a TM helix, and a short cytoplas-
mic tail [reviewed in Ref. (13)]. The CD8α but not CD8β tail binds
to Lck, essential for T cell signaling. Both CD8αα homodimers
and CD8αβ heterodimers are found on the surface of lympho-
cytes, with the CD8αβ heterodimer being the dominant isoform
expressed on CTL (14). The CD8αα isoform is expressed on γδ T
cells, some NK cells, and a subset of intraepithelial lymphocytes
(15). By contrast to CD8, CD4 comprises four Ig-like domains in
tandem with a short stalk region and TM helix, but its cytoplasmic
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tail also binds Lck. In fact, a zinc clasp tethers Lck to the cytoplas-
mic tail of both CD4 and CD8α [Ref. (16) and references therein].
The major function of the co-receptor in T cell-mediated adaptive
responses is to deliver Lck into the TCR-pMHC interacting system
so that exposed ITAM(s) on one or more of the CD3 tails can be
phosphorylated on tyrosine residues. This phosphorylation allows
Zap-70 recruitment and the remainder of downstream signaling
apparatus to assemble (17).
The affinity of CD4 for pMHCII is extremely weak (200µM or
higher) (18) and that of CD8αβ for pMHCI only slightly stronger
(6, 19). By contrast,∼1µM affinities of TCR-pMHC interactions
are not uncommon (20). Thus, the half-life of TCR-pMHC is
∼1000 times longer than that of CD4-pMHC; with little binding
to pMHC contributed by the co-receptor ectodomain per se. The
bidentate interaction of TCR and CD8αβ with a single agonist
pMHC has been studied by a micropipette adhesion assay (21).
Kinetic analysis reveals a two stage cooperative process with the
first stage representing TCR dominant binding to pMHC. The sec-
ond stage binding, delayed by 1 s, is Src-tyrosine kinase-dependent
(i.e., presumably Lck) resulting in the CD8αβ co-receptor bind-
ing to the TCR-engaged pMHC molecule. This time delay may
relate to a required reorientation of the pMHC upon TCR liga-
tion to foster CD8 binding and/or other intracellular molecular
events. This ordered and cooperative trimeric interaction favors
agonist ligands and synergistically augments the bidentate bind-
ing to pMHC in turn linked to T cell signaling. Although not
formally studied as yet, it appears likely that a similar cooperativity
in binding processes will be operative for CD4 and TCR.
THYMOCYTE DEVELOPMENT
αβTCR signaling is essential for adaptive immune responses
as well as thymocyte differentiation (22–28). However, in early
thymic development, the first major checkpoint is referred to as
β-selection. There, TCRβ chain gene rearrangement occurs in
the absence of TCRα chain gene rearrangements such that an
expressed TCRβ chain associates with the invariant pre-Tα (pTα),
forming a pre-TCR on the cell surface (28). Signaling through the
pre-TCR terminates subsequent TCRβ locus rearrangements, res-
cues cells from apoptosis and induces massive proliferation. This
signaling process enables CD4−CD8− double-negative (DN) cells
to differentiate into CD4+CD8+ double-positive (DP) cells, facil-
itating TCRα gene rearrangements and thus generating a large
αβTCR repertoire among DP thymocytes (28). DP thymocytes
undergo positive selection and negative selection following self-
MHC interaction via their αβTCR. During positive selection, DP
cells mature into single positive (SP) CD4+ or CD8+ thymocytes
and may egress into the thymic medulla. After 2 weeks or so of
maturation therein, these SP cells migrate out to the periphery
(29, 30). During negative selection, strongly self-reactive thymo-
cytes undergo cell death. Those apoptotic thymocytes are purged
from the T lineage repertoire [reviewed in Ref. (31–33)].
One remarkable feature of thymic development is the pres-
ence of the numerically major subpopulation of DP thymocytes
expressing both CD4 and CD8 co-receptors. This DP phenotype
is absent from human and murine peripheral T lineages (34). As
Lck is critical for TCR activation and physically associated with
both CD4 and CD8α and DP thymocytes express both of these
co-receptors, it follows that co-receptor-based pMHC interaction
will impose MHC-restricted recognition on the mature αβTCR
repertoire. This was recently tested in an elegant experiment with
knockout mice lacking both co-receptors and MHC class I and
MHC class II proteins. In such “Quattro” knockout mice, Lck
is not sequestered away from the TCR so that TCR functions
in the absence of co-receptor engagement. Hence, TCR signal-
ing is mediated through non-MHC-ligands. Such αβTCRs possess
antibody-like recognition specificities (35, 36).
While the CD4 ectodomain is a rigid concatemer of four Ig-like
domains with no known developmentally regulated glycosylation
and hence, “tuneability,” the structural features of CD8 are quite
different (13). The combined presence of O-glycans and prolines
in the CD8 subunit stalks suggests that these membrane connec-
tors adopt extended and somewhat stiff conformations, similar to
that observed for leukosialin and mucins, nonetheless with some
conformational flexibility (37, 38). This CD8αβ co-receptor flex-
ibility likely accommodates to the variability of TCRαβ docking
onto pMHCI [reviewed in Ref. (11)]. In addition, developmen-
tally regulated glycosylation of the CD8αβ stalk modulates pMHC
binding (13). Immature DP thymocytes bind MHCI more avidly
than CD8 SP thymocytes. This differential binding is governed
by developmentally programed O-glycan modification of several
CD8 stalk threonine residues proximal to the CD8β headpiece
and controlled by ST3Gal-I sialyltransferase (13, 39). ST3Gal-I
specifically localizes to the medulla of the thymus where SP thy-
mocytes reside. ST3Gal-I induction and attendant core 1 sialic acid
addition to CD8β on mature thymocytes decreases CD8αβ-MHCI
avidity by altering CD8αβ domain-domain association and/or
orientation. Hence, glycans on the CD8β stalk appear to mod-
ulate the ability of the distal binding surface of the dimeric CD8
globular head domains to clamp MHCI. The DP stage facilitates
efficient elimination by negative selection of autoreactive TCR
specificities through this enhanced co-receptor function working
in tandem with highly specific TCR-pMHCI triggered apoptosis
(24). Once a thymocyte has differentiated to the CD8 SP stage,
however, CD8αβ O-glycan sialylation reduces the strength of the
CD8αβ co-receptor interaction with pMHCI, mandating a greater
requirement for TCR-pMHCI interaction to achieve a subsequent
activation threshold in mature T lineage cells (13). At the DP thy-
mocyte stage, the higher avidity CD8αβ interaction with pMHCI
will further enforce MHC-restricted αβTCR recognition via Lck
delivery.
LINEAGE FATE
The differentiation of DP thymocytes into CD4+ or CD8+ SP
thymocytes is a fundamental example of bipotential cell fate deter-
mination. How this process is controlled during positive selection
events in the thymus has been the subject of intense scrutiny
[reviewed in Ref. (40)]. A stoichastic selection model that postu-
lates that co-receptor gene expression occurs randomly has been
largely discredited (41). Instructional models postulating that TCR
signals during positive selection specifically direct termination of
irrelevant co-receptors have been controversial. One early strength
of signal model was popular because the CD4 cytoplasmic tail
manifest stronger affinity for Lck than that of CD8α, engendering
TCR/CD4 co-engagement signals stronger than that of TCR/CD8
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(42, 43). However, genetic manipulation of ITAMs within the
TCR complex did not change CD4 vs. CD8 lineage choice (44).
A more recent variant of the instructional model is a duration of
signal model. In this view, TCR signaling of long duration termi-
nates CD8 gene expression while TCR signaling of short duration
terminates CD4 gene expression. Recent data have shown that pos-
itive selection in DP thymocytes per se invariably decreases surface
CD8, thereby selectively disrupting MHC class I-restricted signal-
ing (45). The kinetic signaling model proposed by Singer et al.
incorporates aspects of this signaling duration model in conjunc-
tion with more recent common cytokine receptor γ-chain (γC)
signaling biology (40, 46).
In the kinetic signaling model, positive selection and lineage
choice are sequential events. Positive selection induces all DP
thymocytes, regardless of TCR specificity, to transiently termi-
nate CD8 gene expression resulting in CD4+CD8low thymocytes,
in part by suppressing E8III Cd8 enhancer activity (47). Persis-
tent TCR engagement blocks IL-7 signaling and fosters CD4+ SP
development with loss of CD8. In contrast, disruption of TCR
engagement permits IL-7 signaling and results in “co-receptor
reversal” with CD8 SP development [reviewed in Ref. (47)]. IL-7
signaling induces RUNX3 transcription that initiates CD8 expres-
sion via the E8III Cd8 enhancer and also activates the cytotoxic
gene transcriptome in CD8 T cells. The Cd8 gene locus cis ele-
ments control thymocyte lineage fate with respect to the cytotoxic
vs. helper lineage program (47).
The above thymocyte biology now needs to be interpreted in a
structural context as relates to co-receptor and pMHC interactions
in order to understand bipotential DP thymocyte cell fate deter-
mination in the DP to SP developmental transition. Here we offer
insights into this process with respect to MHC-restricted lineage
development and linkage to mature T cell function.
CONSERVED GEOMETRY OF MHCII α2/β2 DOMAINS FOR
CD4-BINDING
Structures of CD4/MHCII as well as CD8/MHCI complexes have
been solved. These reveal two very different binding modes. CD4
solely uses its N-terminal domain for insertion into a hydropho-
bic cave-like structure formed by the two membrane-proximal
domains of the MHCII molecule (α2/β2). In contrast, CD8 uses
its two dimeric Ig-like domains to clamp onto the CD loop of the
MHCI α3 domain in a fashion similar to an antibody binding to
an antigen (5–7).
We have systematically surveyed herein 58 MHCII structures
and 224 MHCI structures in the protein data bank (PDB). The
structure of human CD4 in complex with HLA-DR1 (PDB code
3S5L) was taken as a reference (48). All other MHC structures were
overlaid onto HLA-DR1 within this 3S5L structure. The superpo-
sition was based on the α2 domain in the case of MHCII molecules
or the corresponding β2M domain in the case of MHCI mole-
cules. Figure 1 depicts this overlay of selected MHC molecules
onto HLA-DR1 in the CD4/HLA-DR1 complex. The represen-
tative MHCII molecules from human or mouse all preserve an
angle between the two membrane-proximal α2/β2 domains that
can readily accommodate CD4-binding (Figure 1A). On the con-
trary, Figures 1B,C show two selected MHCI molecules overlaid,
which have largest (1AGF) or smallest (1QVO) opening angle
between respective membrane-proximalβ2M/α3 domains. Clearly
the MHCI molecules’ geometry appears to prevent CD4-binding.
We have superimposed a representative group of MHCII mole-
cules onto mouse I-Ak in the complex structure of D10 TCR/I-Ak
(1D9K) based on the two membrane-proximal α2/β2 domains,
several of which are pictured in Figure 1A. A larger set includes
human HLA-DR1/TCR complex (1FYT), HLA-DRA/TCR com-
plex (1YMM), HLA-DR2a/TCR complex (1ZGL), HLA-DQ8
(1JK8) as well as mouse I-Au/TCR complex (1U3H), I-Ek (1IEA),
and CD4/I-Ak complex (1JL4). The RMSD value for 178 over-
laid Cα atoms ranges from 0.63 to 1.1 Å, indicating that the two
membrane-proximal domains as a structural unit have a conserved
relative angle. The same calculation was carried out for MHCI
molecules. A representative group of MHCI molecules was super-
imposed onto H2-Kb in the H2-Kb/CD8αα complex structure
(1BQH) based on the two membrane-proximal β2M/α3 domains.
These include human HLA-A (1HHJ), HLA-B (1AGB), HLA-C
(1IM9), HLA-A/TCR complex (1AO7), HLA-A2/CD8αα com-
plex (1AKJ), as well as mouse H2-Kb/TCR complex (2CKB) and
mouse H2-Db (1QLF). The RMSD value for about 180 Cα atoms
ranges from 0.73 to 1.49 Å, indicating that the two membrane-
proximal domains as a structural unit also have a relatively fixed
angle. Notably, the RMSD value for MHCI is slightly larger than
that of MHCII, consistent with previous observation that MHCI
α3 domain has a small angular variation relative to the rest of
MHCI molecule (5). We further compared the separation angles
of the two membrane-proximal domains between the two classes
of MHC molecules. We took the class II molecule HLA-DQ8
(1JK8) and class I molecule H2-Kb in its CD8 complex (1BQH)
for comparison. If the MHCII β2 domain is superimposed onto
the MHCI α3 domain, the rest of the MHCII molecule has about a
38° rotation relative to the counterpart of MHCI. This manifests
as a larger opening between α2 and β2 domains in MHCII com-
pared to between β2M and α3 in MHCI, a geometric requirement
for CD4-binding as shown in Figure 1B. In that figure, MHCII
α2 domain and MHCI β2M domain were overlaid in the back. To
accommodate CD4, the red-colored front β2 domain of MHCII
molecule DR1 appears to “swing” leftwards compared to its coun-
terparts α3 domain of MHCI molecules HLA-A (in yellow) and
HLA-B (in blue).
Figure 2 shows the conserved domain-domain interface inter-
action in the MHCII molecules HLA-DQ8 (1JK8). Figure 2A is the
overview of the structure, whereas the Figure 2B is a zoomed-in
view of the α2/β2 domain interface revealing atomic interaction in
detail. One critical residue is an invariant Trp153 of the β2 domain
(Trp153β) that forms a hydrogen bond to the main chain carbonyl
oxygen of Glu30α from α1 domain. In addition, the indole ring
of this Trp153β is surrounded by three conserved hydrophobic
residues (Phe26α, Leu45α, and Phe48α) of the α1 domain. Since
Trp153β sits on the DE loop, which is itself rigidified by an internal
hydrogen-bond network within the loop (shown in blue broken
lines), this network may play a key role in fixing the β2 domain’s
relative position. Also seen in Figure 2 is an invariant Tyr150α
of the α2 domain that forms a hydrogen bond to the main chain
carbonyl oxygen of Asp152β, just next to Trp153β. This Tyr150α is
located at the E strand of α2 domain’s framework, and along with
other interaction shown in Figure 2 constrains the α2 domain
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FIGURE 1 |The CD4 co-receptor binds to class II but not class I MHC
molecules. (A) Superposition of selected MHCII molecules onto the
structure of the MHCII molecule DR1 in complex with the N-terminal
two-domain of CD4 (PDB code: 3S5L). The superposition is based on the α2
domain. In all cases, the MHCII molecules can accommodate the CD4
N-terminal domain for binding. (B)Two MHCI molecules are superimposed
onto the DR1-CD4 complex structure. Here the β2M domain of MHCI was
overlaid on the α2 domain of DR1 molecule. These two selected MHCI
molecules have the largest (1AGF, in blue) and smallest (1QVO, in yellow)
opening angle, respectively, between the two membrane-proximal domains,
α3 and β2M. Compared with the MHCII DR1-CD4 complex, they do not have
a sufficiently large opening angle to accommodate CD4. (C) Close-up of (B).
so that it maintains a relatively fixed orientation with respect to
the β2 domain. These interface interactions ensure that the α2/β2
domains are positioned suitably for insertion of the N-terminal
domain of CD4 during binding.
Among class II MHC-like molecules, it is interesting to note that
the HLA-DM (1HDM) is structurally distinct from other class II
MHC molecules (49) (Figure 3). HLA-DM has a C′ strand instead
of a D-strand in itsβ2 domain. In all other MHCII molecules, the D
strand plays a critic role in forming a mini-β sheet with the CD4 C′′
strand upon binding (7). Additionally, HLA-DM has a distinct AB
loop protruding out from its β2 domain that would prevent CD4-
binding. DM is not expressed as a cell surface molecule, instead
functioning intracellularly to facilitate peptide loading into other
MHCII molecules. It would appear that HLA-DM is without any
CD4-binding features, consistent with its intracellular role.
THE INVARIANT Gln226 OF MHCI MOLECULES IS THE
DETERMINATE RESIDUE FOR CD8-BINDING
Figure 4A is the overview of the structure of mouse CD8αβ
heterodimer in complex with MHCI molecule H-2Dd (9). The
overall structure is in a good agreement with previously published
complex structures including the mouse CD8αα/H-2Kb (50) and
human CD8αα/HLA-A2 (5) as well as mouse CD8αα homod-
imer in complex with non-classic MHCIb molecule TL (51). That
CD8αβ/H-2Dd complex interaction is clearly distinct from CD4-
binding to an MHCII molecule shown in Figure 1. The major
CD8-binding site is the CD loop of MHCI molecule’s α3 domain,
most notably containing Q226. Importantly, this α3 domain is
the sole contact region for the CD8αβ co-receptor, essential for
cytotoxic T cell function (9).
Of note, there is a very similar CD loop in the β2 domain of
MHCII molecules (7). However, what makes MHCI molecules
unique with respect to CD8-binding is the invariant Gln226 at
the tip of their α3 domain CD loop. The functional importance
of this Gln226 within the CD loop was first reported in 1990
(52). Later, it was further found that this Gln226, but not acidic
residues on the CD loop was critically required (53). Figure 4B
is a detailed view of the Gln226 contact area in the structure of
the CD8αβ/H-2Dd (3DMM). The very tip amide nitrogen forms
bifurcated hydrogen bonds to the Ser37 side chain of the CD8α
subunit (in yellow) and the main chain oxygen of CD8β subunit’s
Pro102 (in gold). Interestingly, we have noticed that the these
hydrogen bonds pull the side chain of Gln226 into an extended
conformation such that the elongated aliphatic portion of this
Gln226 side chain packs onto the aromatic ring of CD8α Tyr55.
This hydrophobic interaction conceivably contributes a signifi-
cant amount of binding energy. Remarkably the Ser37 and Tyr55
are conserved only in CD8α, but not in CD8β subunit, which
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FIGURE 2 | Conserved inter-domain interface in the MHCII molecule
HLA-DQ8 (1JK8) that maintains the inter-domain orientation for
CD4-binding. (A)The overall view of HLA-DQ8. The gold color indicates the α
chain whereas the cyan color defines the β chain. (B) Zoomed-in view of
detailed inter-domain interaction involving particularly W153 at the β chain’s
DE loop (in yellow) and Y150 on the α chain’s E strand (in light brown).
FIGURE 3 | Superposition of the HLA-DM structure onto the DR1-CD4
complex. The superposition is based on the α2 domain. HLA-DM’s α2
domain is in green, whereas the β2 domain is in cyan. Note that DM’s β2
domain does not have a D-strand for pairing to CD4’s C′′-strand necessary
for docking, a key feature of CD4-binding to all MHCII molecules. In
addition, DM’s AB loop protrudes, thereby colliding with CD4.
structurally positions CD8α subunit at the bottom and CD8β sub-
unit on the top shown in the Figure 4. The MHCI CD loop was
noticed to have an extensive internal hydrogen-bond network to
rigidify the loop, supporting the Gln226 for binding (50). These
CD8-binding structural features observed in CD8αβ/H-2Dd are
shared in all known CD8αα/MHCI complex structures. Upon CD8
binding to MHCI, the MHCI molecules’ buried surface area for
structures of HLA-A2/CD8αα, H-2Kb/CD8αα, TL/CD8αα and H-
2Dd/CD8αβ is 1074, 1557, 1645, and 781 Å2, among which a single
Gln226 residue alone contributes 16, 11, 10, and 23%, respectively.
Interestingly for the H-2Dd/CD8αβ complex, since only the MHCI
α3 domain is involved in binding, the buried surface area is smallest
but with Gln226 makes the highest contribution.
In summary, whereas MHCII molecules have their α2/β2
domains arranged in a conserved and opened conformation suit-
able for CD4 N-terminal domain insertion for binding, MHCI
molecules are unique in having a key invariant Gln226 at the tip
of their α3 domain’s CD loop. The latter is well-positioned to
extend into the crevice formed between two CD8 subunits for
specific interactions. These observations apply to the 58 MHCII
and 224 MHCI structures of both human and murine origin
examined.
SEQUENTIAL αβTCR-pMHC INTERACTION AND
CO-RECEPTOR DELIVERY OF Lck IS LINKED TO CD4/8 GENE
IMPRINTING
The above structural scrutiny leads us to propose the follow-
ing heuristic. On developing DP thymocytes, there are clonally
distributed MHCI- or MHCII-restricted TCRs that can poten-
tially interact with the antigen presenting platforms of MHCI
(α1α2 domains) and MHCII (α1β1 domains) molecules extend-
ing from the stromal cell surface. The interacting domains of
both TCR and MHC molecules have no intrinsic structural dif-
ferences that distinguish the two classes of MHC interactions;
nor are TCR complex components distinct in overall structural
features vis-à-vis the individual subunits (11). It is difficult,
therefore, to conceive that such TCR-pMHC interactions would
direct a differential switch-off of either CD4 or CD8 co-receptors.
Instead, the preference of the TCR for a specific pMHC dictates
which co-receptor then enters into the preformed TCR-pMHC
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FIGURE 4 | Structure of mouse CD8αβ in complex with the MHCI
molecule H-2Dd. (A) An overview of the complex. (B) Details of the
binding region. Note that the key conserved Q226 from MHCI
molecule’s CD loop pokes into a crevice formed between CD8α and β
subunits, making hydrogen bonds to conserved S37 of the CD8α
subunit, while the aliphatic portion of this Q226 is involved in
extensive hydrophobic contacts with the conserved Y55 of the CD8α
subunit.
complex. During positive selection, DP thymocytes first become
intermediate cells (CD4+CD8low). If during positive selection, one
MHCII-restricted TCR on the CD4+CD8low cell surface encoun-
ters an MHCII molecule that presents a self-peptide on the stromal
cell, the “snug” fit of CD4 into the MHCII molecule’s α2/β2
domains on the cell surface as described above brings Lck into
close proximity with exposed CD3 cytoplasmic tail ITAMs in the
TCR complex. If successful ITAM phosphorylation and down-
stream activation persists, transcriptional factors like GATA3 and
Th-POK are induced and that induction promotes CD4+ T cell
differentiation by preventing Cd4 gene silencing (40). This suc-
cessful signaling eventually terminates any CD8 expression, and
the thymocyte differentiates into CD4+ SP cell. If during positive
selection an MHCI-restricted TCR on one CD4+CD8low thymo-
cyte surface encounters an MHCI that presents a self-peptide, then
CD4 fails to contact the MHCI molecule. Consequently, TCR sig-
naling is disrupted with loss of GATA3 and Th-POK transcription.
Instead, IL-7R signaling is initiated to up-regulate RUNX3, thereby
silencing Cd4 and activating Cd8 expression. CD8 co-receptor
function is operative. As RUNX3 is also linked to the cytotoxic pro-
gram, this dichotomy normally ensures that CD8 SP development
is coupled to the CTL program.
As both human and mouse TCRs manifest ∼10-fold greater
3-D binding affinities for pMHCI compared to pMHCII cognate
ligands (54, 55), the relatively persistent interaction of class II
MHC-restricted TCRs with pMHCI ligands in the thymus as pos-
tulated above may appear paradoxical. However, recent studies
show that TCR-triggered interaction with pMHC is force depen-
dent, dramatically modifying TCR-pMHC bond lifetimes (56, 57).
Such bond lifetime alteration is not predicted by 3-D affinity
measurements. Furthermore, the trimolecular TCR-pMHC-co-
receptor interaction likely alters the landscape of bond lifetimes
further, particularly under a force load, as would occur when thy-
mocytes scan thymic epithelial cells. That said, other differences
in CD4 vs. CD8 lineage-specific death rates at the DP thymocyte
branch point imply additional biological parameters modulating
developmental progression (58).
CONCLUDING REMARKS
Since the introduction of TCR transgenic mouse studies, it has
been clear that the interaction of the TCR in a DP thymocyte
with a specific thymic pMHC molecule determines differentia-
tion of that DP thymocyte to either a CD4 or CD8 SP thymocyte
(59). The paradox that there were no overall architectural distinc-
tions between TCRs that recognize peptides bound to MHCI vs.
bound to MHCII molecules as revealed by structural analysis made
this finding enigmatic [reviewed in Ref. (11)]. From our extensive
structure data survey, it is now clear that the ability of CD4 to bind
pMHCII and CD8 to bind to pMHCI molecules is inviolate. TCR
recognition of antigen is MHC-restricted due to the requirement
for co-receptor-mediated delivery of Lck to the TCR-pMHC com-
plex during positive selection. Transient loss of CD8 expression
that accompanies positive selection of all DP thymocytes supports
a prolonged CD4 co-receptor dependent interaction of class II
MHC-restricted TCRs on thymocytes with pMHCII on stromal
cells. By comparison, the corresponding CD8 co-receptor depen-
dent interaction of class I MHC-restricted TCRs with pMHCI is
attenuated. In the latter case, TCR-pMHCI signaling is disrupted,
IL-7R signaling permitted and consequently, RUNX3 triggers the
cytotoxic transcriptome program. Thus, the specificity for CD4 vs.
CD8 SP lineage commitment is coupled to the co-receptor based
on a given TCR’s pMHC class preference. In contrast, effector func-
tion is linked to cytokine receptor-mediated signaling events that
control downstream cellular transcriptional programs.
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